The manufacturing of the drug will be retained by TJ Biopharma at its site in Hangzhou, which would make felzartamab China’s ...
The EMA’s CHMP has stated its positive opinions on three drugs for autoimmune, muscle wasting and rare genetic diseases.
Biogen heads into Q1 earnings with new drugs like Skyclarys and Zurzuvae driving growth as legacy MS products face rising competitive pressure.
North Longford woman Kiara Lynch recently met with local TD Micheál Carrigy to discuss her campaign calling on the HSE to ...
MedPage Today on MSN
Real-world registry study shows Alzheimer's drug safety outcomes
No new signals for lecanemab emerged in ALZ-NET ...
MedPage Today on MSN
Cell therapy slows upper limb decline in Duchenne muscular dystrophy
Investigational deramiocel is back under FDA review again ...
Well, I read the upgrade today by Wells Fargo, and it talked about a bunch of revenue streams. including Alzheimer’s, and it ...
While Big Pharmas embarked on a frenzy of acquisitions over recent weeks, Roche’s CEO has explained to Fierce Biotech why the ...
Biogen (NASDAQ:BIIB) picked up a strong endorsement from Wall Street on Wednesday, as UBS analyst Michael Yee upgraded the ...
In this article, we will look at Jim Cramer’s stock calls on Mad Money recently. The host of Mad Money said Monday that the ...
Biogen Inc. (NASDAQ: BIIB) has recently been upgraded to a “Buy” rating by UBS analyst Michael Yee, with a new price target set at $225, signaling strong upside potential from the current trading ...
Futures are trading higher as we hit the midweek point. All major indices finished lower on Tuesday as the deadline for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results